Stock 600521 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Zhejiang Huahai Pharmaceutical Co., Ltd.

Equities

600521

CNE000001DL5

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-21 pm EDT 		5-day change 1st Jan Change
15.71 CNY +3.36% Intraday chart for Zhejiang Huahai Pharmaceutical Co., Ltd. +6.15% +7.09%
Apr. 19 Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. CI
Apr. 17 Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.
CI
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets
MT
Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 14, 2023 has closed with 7,023,600 shares, representing 0.48% for CNY 99.99 million.
CI
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit
MT
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets
MT
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.
CI
Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.
CI
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection
MT
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets
MT
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets
MT
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
CI
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion
MT
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares
MT
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug
MT
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Huahai Pharma Registers Drug for Prostate Treatment
MT
Ningbo Menovo Pharma Registers Blood Pressure Drug
MT
Huahai Pharmaceutical Gets US FDA's Nod for Dicyclomine Hydrochloride Capsules
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600521 Stock
  4. News Zhejiang Huahai Pharmaceutical Co., Ltd.